Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CCNH | P51946 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4661 | 0.88 | CA1 (0.57) | CA1CA2CA5ACA9CES2 | |
| SCHEMBL29824423 | 0.88 | CA1 (0.57) | CA1CA2CA5ACA9CES2 | |
| SCHEMBL1504972 | 0.86 | CA1 (0.55) | CA1CA2CA5ACA9CES2 | |
| SCHEMBL1907531 | 0.86 | CA1 (0.53) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1504913 | 0.86 | CA1 (0.55) | CA1CA2CA5ACA9CES2 | |
| Hydrazine SCHEMBL28339222 | 0.82 | CA1 (0.56) | CA1CA2CA5ACA9CES2 | |
| Bicarbonate SCHEMBL28555116 | 0.81 | CES2 (0.53) | CA1CA2CA5ACA9CES2 | |
| SCHEMBL27365264 | 0.79 | ALDH1A1 (0.46) | CA1CA2CA5ACA9MMP2 | |
| SCHEMBL1139725 | 0.78 | PTPN1 (0.47) | CA1CA2CA5ACA9MMP1 | |
| SCHEMBL2033058 | 0.78 | MEN1 (0.50) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-109311839-A | Methylamine derivative is used for treating cancer as lysyl oxidase inhibitor | 癌症研究协会皇家癌症医院 | 2019-02-05 | — | — | CN | disclosed |
| CN-104168958-B | Diaryl sulfonamides useful for the treatment of inflammation and cancer | 坎塞拉有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107148417-A | Benzo-aza * sulfonamide compounds | 豪夫迈·罗氏有限公司 | 2017-09-08 | — | — | CN | disclosed |
| CN-104678028-B | The pre-treatment of biological original amine neurotransmitters and detection method and detection kit | 中国人民解放军军事医学科学院毒物药物研究所 | 2017-08-15 | — | — | CN | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| CN-102036961-B | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2014-02-26 | — | — | CN | disclosed |
| CN-1980897-A | 4-phenyl-pyrimidine-2-carbonitrile derivatives | ORGANON NV (NL) | 2007-06-13 | — | — | CN | disclosed |
| EP-1786811-A2 | TRIAZOLOPYRIDINE COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1781655-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1758870-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006018735-A2 | TRIAZOLOPYRIDINE COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
| CN-1037568-C | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1998-03-04 | — | — | CN | disclosed |
| CN-1165143-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
| CN-1165144-A | Phosphosulfonate herbicides | ROHM & HAAS (US) | 1997-11-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | CA1 1546/4885CA2 3216/4885CA5A 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.